Mackenzie Financial
KDNY

Mackenzie Financial’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Mackenzie Financial’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-2,042
Closed -$25K – 1105
2020
Q3 		$25K Sell
2,042
-278
-12% -$3.73K ﹤0.01% 982
2020
Q2 		$27K Buy
+2,320
New +$32K ﹤0.01% 994

Other funds holding KDNY

ALSV
ATP Life Science Ventures New York $898M AUM 84.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Mackenzie Financial's KDNY Position: Q4 2020 in Review

Mackenzie Financial sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q4 2020, closing a stake of 2,042 shares — an estimated $25K sold.

Mackenzie Financial first reported a position in KDNY in Q2 2020 and held it in 2 quarters. The position peaked at $27K in Q2 2020. 77 funds tracked by Wall St. Rank hold KDNY as of Q4 2020.

  • Mackenzie Financial reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Mackenzie Financial sold 2,042 Chinook Therapeutics, Inc. Common Stock shares in Q4 2020, an estimated $25K.
  • Mackenzie Financial first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2020 and held it in 2 quarters.
  • Mackenzie Financial's Chinook Therapeutics, Inc. Common Stock position peaked at $27K in Q2 2020.
  • 77 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q4 2020.

Based on Mackenzie Financial's 13F filing for Q4 2020, filed 10 Feb 2021.